$NKTR: Nektar -5.9% as it reports urothelial cancer study

Date: Monday, February 11th, 2019

Stock(s) mentioned:

Source: Seeking Alpha (https://seekingalpha.com)

Summary: Nektar Therapeutics (NASDAQ:NKTR) is 5.9% lower postmarket after it reported a response rate of 48% in its study of treatment for urothelial cancer. That rate …

Full article address: https://seekingalpha.com/news/3431934-nektar-minus-5_9-percent-reports-urothelial-cancer-study

Related News:

$NKTR: Dow Eyes 3 Straight Wins as Rebound Hits High Gear

$NKTR: Nektar Therapeutics Announces Five Accepted Abstracts at 2019 …

$SPX $TPR $NKTR $PRGO $MYL: 8 Stocks Thriving on a Brutal Day for the Market

$BMY $GILD $NKTR $TAK: Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y

$NKTR: What You’ll Want to Know About Nektar Therapeutics’ Q1 Earnings …

$NKTR: Nektar Therapeutics (NKTR) Q1 2019 Earnings Call Transcript

$NKTR: Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2019 …

$NKTR: Nektar Q1 top line down 26%, cash consumption up 54%

$NKTR: Nektar Therapeutics Q1 2019 Earnings Preview

$NKTR: Nektar Therapeutics Expected to Lose 69 Cents a Share

$BMY $PFE $HZNP $NKTR: What’s in the Cards for Nektar (NKTR) This Earnings Season?

Latest News:

$SPY $BABA: If a popular options strategy suddenly implodes, be ready to scoop up cheap blue chips

$GE: Is General Electric a Buy?

$HD $URBN: Home Depot, Target, HP, Best Buy and More Major Earnings …

$TMUS: Masayoshi Son: Genius or insane? Maybe neither

$DAL $ALK $LUV $NFLX $UAL: Delta’s test of free in-flight Wi-Fi may shame other airlines into offering service

$AVTR $FSLY $LK $LYFT $PINS $UBER: Why the IPO Boom Will Continue

$SBUX: Millions of Americans Could Miss Work Tomorrow After the ‘Game of Thrones’ Finale

$AMZN $OXY $APC $WFC $SRE: Want to invest like Warren Buffett? Here are the ins and outs of buying preferred stock

$TSLA $GM: Tesla fires could dampen electric car sales as industry ramps up EV production, auto analysts say

$ROKU $GH $CVNA: 3 Stocks That Have Doubled in 2019 — Are They Still Buys?

$AXSM: Here’s Why You’ll Regret Ignoring This Biotech Stock Rocket